Member of Technical Staff, Biological World Models (Staff+ Level)
Parallel Bio
Summary
Drug discovery has a translation problem: more than 95% of drugs that succeed in animal models fail in humans. We're building the alternative: human-first drug discovery, powered by organoids and AI, running on real human biology from the very first experiment.
Job description
The Mission
Drug discovery has a translation problem: more than 95% of drugs that succeed in animal models fail in humans. We're building the alternative: human-first drug discovery, powered by organoids and AI, running on real human biology from the very first experiment.
Our platform is 87% concordant with clinical patient data - a vast improvement over the 3% translational success rate of animals. We've demonstrated the ability to model immunotoxicology, immunogen stimulation, and two autoimmune diseases with more on the way. Numerous pharma partners including 3 Fortune 500 companies are already using the platform.
The opportunity ahead of the company is generational: build the first scaled engine for generating real human biological data, and use it to fundamentally change how medicines are discovered.
Train AI world models of biology
Requirements
- Staff+ level experience in AI and biological modeling
- Strong background applying computational methods to human-first drug discovery
- Expertise in artificial intelligence and machine learning
- Experience with biological modeling and computational biology
- Ability to work with organoid platforms and clinical patient data
Company overview
Parallel Bio is an innovative biotechnology company pioneering human-first drug discovery through its groundbreaking platform that combines immune organoids with artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts with additional locations in San Diego and San Francisco, the company has developed the world's first human "immune system in a dish" technology. Their platform creates 3D mini-models of human organs (organoids) that accurately replicate human immune responses, enabling more effective drug testing and immunotherapy development. By integrating AI with these advanced biological models, Parallel Bio aims to revolutionize pharmaceutical development by predicting drug safety and efficacy across diverse populations before clinical trials. The company has raised significant funding, including a $21 million Series A round in 2025, and focuses on addressing major healthcare challenges like cancer, autoimmune diseases, and age-related degeneration through their unique approach that reduces reliance on animal testing while improving drug success rates.